Blockade of Na+ Channels in Pancreatic α-Cells Has Antidiabetic Effects
The DOI matches its Crossref record; 38 of the 41 references it cites were found in a registry or an index.
Abstract
Pancreatic α-cells express voltage-gated Na+ channels (NaChs), which support the generation of electrical activity leading to an increase in intracellular calcium, and cause exocytosis of glucagon. Ranolazine, a NaCh blocker, is approved for treatment of angina. In addition to its antianginal effects, ranolazine has been shown to reduce HbA1c levels in patients with type 2 diabetes mellitus and coronary artery disease; however, the mechanism behind its antidiabetic effect has been unclear. We tested the hypothesis that ranolazine exerts its antidiabetic effects by inhibiting glucagon release via blockade of NaChs in the pancreatic α-cells. Our data show that ranolazine, via blockade of NaChs in pancreatic α-cells, inhibits their electrical activity and reduces glucagon release. We found that glucagon release in human pancreatic islets is mediated by the Nav1.3 isoform. In animal models of diabetes, ranolazine and a more selective NaCh blocker (GS-458967) lowered postprandial and basal glucagon levels, which were associated with a reduction in hyperglycemia, confirming that glucose-lowering effects of ranolazine are due to the blockade of NaChs. This mechanism of action is unique in that no other approved antidiabetic drugs act via this mechanism, and raises the prospect that selective Nav1.3 blockers may constitute a novel approach for the treatment of diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ranolazine appears to reduce HbA1c by ≈0.5% to 0.7% via a reduction in glucagon secretion”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [258]
Citations
Cites
共やくエクイン・エストロゲン(Premarin)服用閉経婦人の血清エクイリン,エストロン,エストラジオール値
Whittaker, P. G., Morgan, M. R., Dean, P., Cameron, E., & Lind, T. (1980) · The Lancet · Cited by 724
Adult insulin- and glucagon-producing cells differentiate from two independent cell lineages
Herrera, P. L. (2000) · Development · doi:10.1242/dev.127.11.2317 · Cited by 672
Incretin-based therapies for type 2 diabetes mellitus
Lovshin, J. A., & Drucker, D. J. (2009) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2009.48 · Cited by 649 · cited 1×
“The effect was similar to that reported with GLP-1 receptor agonists, which also inhibit glucagon secretion, albeit via a different mechanism (27).”
The essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599 · cited 3×
“Glucagon as a Target for Diabetes The abnormal glucagon secretion in T2DM and its key role in the development of fasting and postprandial hyperglycemia has recently been a focus of attention (1,7,29).”
InfluentialChaitman, B. R., Skettino, S. L., Parker, J. O., Hanley, P., Meluzin, J., Kuch, J., Pepine, C. J., Wang, W., Nelson, J. J., Hebert, D. A., et al. (2004) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2003.11.045 · Cited by 567 · cited 1×
“Ranolazine is an anti-anginal drug with cardioprotective properties (12).”
BackgroundBelardinelli, L., Shryock, J. C., & Fraser, H. (2006) · Heart · doi:10.1136/hrt.2005.078790 · Cited by 386
Self-citationShah, P., Vella, A., Basu, A., Basu, R., Schwenk, W. F., & Rizza, R. A. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.11.6993 · Cited by 368 · cited 1×
“This hyperglucagonemia increases hepatic glucose production, thereby contributing importantly to diabetic hyperglycemia (4,5).”
Glucagon receptor knockout prevents insulin-deficient type 1 diabetes in mice
Lee, Y., Wang, M.-Y., Du, X. Q., Charron, M. J., & Unger, R. H. (2011) · Diabetes · doi:10.2337/db10-0426 · Cited by 327 · cited 1×
“Therefore, suppression of glucagon secretion or inhibition of its action in the liver constitutes potential therapeutic targets for diabetes (30-32).”
REAVEN, G. M., CHEN, Y.-D. I., GOLAY, A., SWISLOCKI, A. L. M., & JASPAN, J. B. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-1-106 · Cited by 326 · cited 1×
“Plasma glucagon levels are increased under both fasting and postprandial states in diabetes (2,3).”
MacDonald, P. E., Marinis, Y. Z. D., Ramracheya, R., Salehi, A., Ma, X., Johnson, P. R. V., Cox, R., Eliasson, L., & Rorsman, P. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050143 · Cited by 246 · cited 1×
“These findings are consistent with previous reports demonstrating that NaChs can directly modulate glucagon secretion in intact islets obtained from non-diabetic rodents and humans (8-11, 22, 23).”
ResultGöpel, S. O., Kanno, T., Barg, S., Weng, X. ‐., Gromada, J., & Rorsman, P. (2000) · The Journal of Physiology · doi:10.1111/j.1469-7793.2000.00509.x · Cited by 229 · cited 2×
“It is known that α-cells express Tetrodotoxin (TTX)-sensitive NaCh isoforms and NaCh blockers like TTX inhibits glucagon secretion (8-10).”
BackgroundResultHyperglucagonemia in diabetic ketoacidosis
Müller, W. A., Faloona, G. R., & Unger, R. H. (1973) · The American Journal of Medicine · doi:10.1016/0002-9343(73)90083-1 · Cited by 220 · cited 1×
“Plasma glucagon levels are increased under both fasting and postprandial states in diabetes (2, 3).”
BackgroundSloop, K. W., Cao, J. X.-C., Siesky, A. M., Zhang, H. Y., Bodenmiller, D. M., Cox, A. L., Jacobs, S. J., Moyers, J. S., Owens, R. A., Showalter, A. D., et al. (2004) · Journal of Clinical Investigation · doi:10.1172/jci200420911 · Cited by 219 · cited 2×
“Results of studies with glucagon receptor antagonists (peptide and small molecule), antisense oligonucleotides and glucagon receptor knock-out mice show that elimination or inhibition of glucagon receptor signaling has strong anti-hyperglycemic effects in various animal models of diabetes (31, 33-35).”
BackgroundPetersen, K. F., & Sullivan, J. T. (2001) · Diabetologia · doi:10.1007/s001250100006 · Cited by 209 · cited 2×
“Therefore, suppression of glucagon secretion or inhibition of its action in the liver constitutes potential therapeutic targets for diabetes (30-32).”
Tight coupling between electrical activity and exocytosis in mouse glucagon-secreting alpha-cells.
Barg, S., Galvanovskis, J., Göpel, S. O., Rorsman, P., & Eliasson, L. (2000) · Diabetes · doi:10.2337/diabetes.49.9.1500 · Cited by 209
Liver-Specific Disruption of the Murine Glucagon Receptor Produces α-Cell Hyperplasia
Longuet, C., Robledo, A. M., Dean, E. D., Dai, C., Ali, S., McGuinness, I., de Chavez, V., Vuguin, P. M., Charron, M. J., Powers, A. C., et al. (2013) · Diabetes · doi:10.2337/db11-1605 · Cited by 206
Effects of ranolazine on exercise tolerance and HbA1c in patients with chronic angina and diabetes
Timmis, A. D., Chaitman, B. R., & Crager, M. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehi495 · Cited by 193 · cited 5×
“The abnormal glucagon secretion in T2DM and its key role in the development of fasting and postprandial hyperglycemia has recently been a focus of attention (1,7,29).”
InfluentialFailure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM
Dinneen, S., Alzaid, A., Turk, D., & Rizza, R. (1995) · Diabetologia · doi:10.1007/bf00400639 · Cited by 190 · cited 1×
“This hyperglucagonemia increases hepatic glucose production, thereby contributing importantly to diabetic hyperglycemia (4,5).”
Belardinelli, L., Liu, G., Smith-Maxwell, C., Wang, W.-Q., El-Bizri, N., Hirakawa, R., Karpinski, S., Hong Li, C., Hu, L., Li, X.-J., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.198887 · Cited by 187 · cited 1×
“Ranolazine and GS-458967 (triazolopyridine derivative, 6-(4-(trifluoromethoxy)phenyl)3-(trifluoromethyl)-[1,2,4]triazolo[4,3-a]pyridine) (19) were synthesized by Gilead Sciences.”
Self-citationMorrow, D. A., Scirica, B. M., Chaitman, B. R., McGuire, D. K., Murphy, S. A., Karwatowska-Prokopczuk, E., McCabe, C. H., & Braunwald, E. (2009) · Circulation · doi:10.1161/circulationaha.107.763912 · Cited by 170 · cited 3×
“Data from the MERLIN-TIMI-36 study demonstrated that ranolazine lowered HbA1c in diabetics and reduced the incidence of newly elevated HbA1c in initially normoglycemic patients (15, 16).”
BackgroundMethodResultGlycemic Control in Mice with Targeted Disruption of the Glucagon Receptor Gene
Parker, J. C., Andrews, K. M., Allen, M. R., Stock, J. L., & McNeish, J. D. (2002) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2001.6265 · Cited by 162
Ramracheya, R., Ward, C., Shigeto, M., Walker, J. N., Amisten, S., Zhang, Q., Johnson, P. R., Rorsman, P., & Braun, M. (2010) · Diabetes · doi:10.2337/db09-1505 · Cited by 136
Glucagon antagonism as a potential therapeutic target in type 2 diabetes
Bagger, J. I., Knop, F. K., Holst, J. J., & Vilsbøll, T. (2011) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01427.x · Cited by 124 · cited 1×
“Glucagon as a target for diabetes The abnormal glucagon secretion in T2DM and its key role in development of fasting and postprandial hyperglycemia has been the focus of attention recently (1, 7, 29).”
BackgroundGlucagon Receptor Knockout Mice Display Increased Insulin Sensitivity and Impaired β-Cell Function
Sørensen, H., Winzell, M. S., Brand, C. L., Fosgerau, K., Gelling, R. W., Nishimura, E., & Ahren, B. (2006) · Diabetes · doi:10.2337/db06-0307 · Cited by 121 · cited 1×
“Therefore, suppression of glucagon secretion or inhibition of its action in the liver constitutes potential therapeutic targets for diabetes (30-32).”
BackgroundCharacterization of voltage‐dependent sodium and calcium channels in mouse pancreatic A‐ and B‐cells
Vignali, S., Leiss, V., Karl, R., Hofmann, F., & Welling, A. (2006) · The Journal of Physiology · doi:10.1113/jphysiol.2005.102368 · Cited by 96 · cited 2×
“It is known that α-cells express Tetrodotoxin (TTX)-sensitive NaCh isoforms and NaCh blockers like TTX inhibits glucagon secretion (8-10).”
BackgroundResultHassan, R. H., Hainault, I., Vilquin, J., Samama, C. M., Lasnier, F., Ferré, P., Foufelle, F., & Hajduch, É. (2011) · Diabetologia · doi:10.1007/s00125-011-2328-9 · Cited by 93
Yang, J., MacDougall, M. L., McDowell, M. T., Xi, L., Wei, R., Zavadoski, W. J., Molloy, M. P., Baker, J. D., Kuhn, M., Cabrera, O., et al. (2011) · BMC Genomics · doi:10.1186/1471-2164-12-281 · Cited by 82 · cited 1×
“The glucose-lowering effects of glucagon receptor antagonists are also associated with increases in levels of glucagon, liver enzymes, and LDL cholesterol, and in a-cell hypertrophy and hyperplasia (37,38).”
Chisholm, J. W., Goldfine, A. B., Dhalla, A. K., Braunwald, E., Morrow, D. A., Karwatowska-Prokopczuk, E., & Belardinelli, L. (2010) · Diabetes Care · doi:10.2337/dc09-2334 · Cited by 78 · cited 15×
“P H A R M A C O L O G Y A N D T H E R A P E U T IC S Study (Metabolic Efficiency with Ranolazine for Less Ischemia in Non-ST Elevation Acute Coronary Syndromes Study) demonstrated that ranolazine lowered HbA1c levels in patients with diabetes and reduced the incidence of newly elevated HbA1c levels in initially normog…”
InfluentialSelf-citationNing, Y., Wei, Z. C., Fu, Z., Jiang, J. Z., Liu, D., Belardinelli, L., & Dhalla, A. K. (2011) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.176396 · Cited by 75
Self-citationThe Alpha-Cell as Target for Type 2 Diabetes Therapy
Christensen, M., Bagger, J. I., Vilsboll, T., & Knop, F. K. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.369 · Cited by 65 · cited 1×
“Therefore, not surprisingly, the lowering of glucagon levels or antagonizing its actions via blockade of glucagon receptors can significantly reduce hyperglycemia (6,7).”
Le Marchand, S. J., & Piston, D. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047084 · Cited by 58 · cited 1×
“A recent report demonstrated no effect of TTX on glucagon release (24) however; the reason(s) for this discrepancy are not well-understood.”
BackgroundHuang, Y.-C., Rupnik, M. S., Karimian, N., Herrera, P. L., Gilon, P., Feng, Z.-P., & Gaisano, H. Y. (2013) · Diabetes · doi:10.2337/db11-0786 · Cited by 54 · cited 4×
“reported that pancreatic α-cells of diabetic mice, with chronic hyperglucagonemia, had increased Na + current (INa), action potential duration, amplitude and firing frequency and increased glucagon content which primes the cells for increased glucagon release (11).”
BackgroundResultInfluentialGlucagon as a Critical Factor in the Pathology of Diabetes
Edgerton, D. S., & Cherrington, A. D. (2011) · Diabetes · doi:10.2337/db10-1594 · Cited by 47
Autonomic Mediation of Glucagon Secretion During Insulin-Induced Hypoglycemia in Rhesus Monkeys
Havel, P. J., & Valverde, C. (1996) · Diabetes · doi:10.2337/diab.45.7.960 · Cited by 40
Meier, J. J., Ueberberg, S., Korbas, S., & Schneider, S. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00315.2010 · Cited by 35
The Use of Iodixanol for the Purification of Rat Pancreatic Islets
Dellê, H., Saito, M., Yoshimoto, P. M., & Noronha, I. L. (2007) · Transplantation Proceedings · doi:10.1016/j.transproceed.2007.01.039 · Cited by 27 · cited 1×
“Pancreatic islets were isolated from male SD rats (300– 400 g) using Liberase TL (Roche Diagnostics, Dallas, TX) and Ficoll gradients (Mediatech, Manassas, VA) (20).”
Hirakawa, R., El‐Bizri, N., Shryock, J. C., Belardinelli, L., & Rajamani, S. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.01.021 · Cited by 21 · cited 1×
“3 with half-maximal inhibitory concentration values of 12 mmol/L (26) and 0.”
Self-citationZhang, Q., Ramracheya, R. D., Bengtsson, M., Braun, M., Welling, A., & Rorsman, P. (2012) · Diabetologia · Cited by 1
Research works printed but not linked: 1
- Prince, 2011, Short-term treatment with glucagon receptor antagonist LY2409021 effectively reduces fasting blood glucose (FBG) and HbA1c in patients with type 2 diabetes mellitus, Diabetologia, 54, S86
Cited by
Voltage-gated sodium channels: structure, function, pharmacology, and clinical indications
de Lera Ruiz, M., & Kraus, R. L. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501981g · Cited by 548
Arnold, S. V., Bhatt, D. L., Barsness, G. W., Beatty, A. L., Deedwania, P. C., Inzucchi, S. E., Kosiborod, M., Leiter, L. A., Lipska, K. J., Newman, J. D., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000766 · Cited by 304
A method for the generation of human stem cell-derived alpha cells
Peterson, Q. P., Veres, A., Chen, L., Slama, M. Q., Kenty, J. H. R., Hassoun, S., Brown, M. R., Dou, H., Duffy, C. D., Zhou, Q., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16049-3 · Cited by 92
Concomitant Diabetes Mellitus and Heart Failure
Dei, A., Fonarow, G. C., Gheorghiade, M., & Butler, J. (2014) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2014.09.002 · Cited by 94
Cassano, V., Leo, A., Tallarico, M., Nesci, V., Cimellaro, A., Fiorentino, T. V., Citraro, R., Hribal, M. L., Sarro, G. D., Perticone, F., et al. (2020) · Nutrients · doi:10.3390/nu12020382 · Cited by 69
Metadata
- Authors
- Dhalla, A. K., Yang, M., Ning, Y., Kahlig, K. M., Krause, M., Rajamani, S., & Belardinelli, L.
- Affiliations
- Gilead Sciences (United States) (US)
- Corresponding author
- Dhalla, Arvinder K.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-09-15
- Volume
- 63
- Issue
- 10
- Pages
- 3545-3556
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2151219840
- Cited by
- 53
- References
- 41
- Citations by year
- 2025: 6 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 6 · 2020: 6 · 2019: 3 · 2018: 4 · 2017: 7 · 2016: 8 · 2015: 4 · 2014: 3
- FWCI
- 7.60
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ion channel regulation and function
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- ranolazine, Nav1.3, voltage-gated sodium channels, alpha cells, glucagon secretion, type 2 diabetes, antidiabetic mechanism, hyperglycemia, pancreatic islets, intracellular calcium
- MeSH terms
- Ranolazine, Acetanilides, Animals, Diabetes Mellitus, Experimental, Exocytosis, Glucagon, Humans, Hypoglycemic Agents, Islets of Langerhans, Male, Piperazines, Rats, Sprague-Dawley, Sodium Channel Blockers, Glucagon-Secreting Cells, Rats, NAV1.3 Voltage-Gated Sodium Channel
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.